Overexpression of PEP-19 suppresses angiotensin II-induced cardiomyocyte hypertrophy

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Cell Signaling

Background:

• Cardiac hypertrophy involves dysregulated intracellular signaling, but the role of endogenous calmodulin regulators like PEP-19 is unclear.
• Understanding PEP-19's function could reveal new therapeutic targets for cardiac hypertrophy.

Purpose of the Study:

• To investigate the role of PEP-19 in cardiac hypertrophy.
• To determine if PEP-19 can modulate key signaling pathways involved in cardiac hypertrophy.

Main Methods:

• PEP-19 protein levels were assessed in an in vivo aortic banding model and in vitro angiotensin II-induced cardiomyocyte hypertrophy.
• The effects of PEP-19 transfection on CaMKII, calcineurin activation, hypertrophy-related gene expression (ANP, BNP), and sarcoplasmic reticulum Ca(2+) handling were evaluated.

Main Results:

• PEP-19 protein levels were significantly increased in both in vivo and in vitro models of cardiac hypertrophy.
• PEP-19 transfection inhibited angiotensin II-induced cardiomyocyte hypertrophy, suppressed CaMKII and calcineurin activation, and reduced the expression of ANP and BNP.
• PEP-19 also ameliorated angiotensin II-induced increases in phospho-phospholamban and sarcoplasmic reticulum Ca(2+) release.

Conclusions:

• PEP-19 plays a protective role in cardiac hypertrophy by attenuating angiotensin II-induced signaling.
• PEP-19 suppresses CaMKII and calcineurin pathways, offering a potential therapeutic strategy for cardiac hypertrophy.